Migraine treatment in thailand: what helps and hinders eptinezumab use?

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Target Population * Group 1: Patients who were diagnosed migraine with or without aura or chronic migraine and have received eptinezumab. * Group 2: Healthcare providers (e.g. doctor, outpatient nurse and daycare nurse) who are responsible for providing eptinezumab to the patients. * Inclusion Criteria Group 1: People with migraine with or without aura or chronic migraine Inclusion criteria Group 1A 1. Age ≥ 18 years 2. Diagnosed with migraine with or without aura or chronic migraine according to the International Classification of Headache Disorders, 3rd edition (ICHD-3)\* 3. Have received eptinezumab infusion at the King Chulalongkorn Memorial Hospital (KCMH) 4. Have received other CGRP mAbs prior to starting eptinezumab 5. Able to communicate in Thai fluently 6. Provide informed consent Group 1B <!-- --> 1. Age ≥ 18 years 2. Diagnosed with migraine with or without aura or chronic migraine according to the ICHD-3\* 3. Have received eptinezumab infusion at the KCMH 4. Have NEVER received any CGRP mAbs prior to starting eptinezumab 5. Able to communicate in Thai fluently 6. Provide informed consent \* The diagnosis will be established by consensus between two headache specialists. In case of a discrepancy, conflicts will be resolved through a final consensus agreement between the two specialists prior to enrollment. Group 2: Healthcare providers Inclusion criteria <!-- --> 1. Age ≥ 18 years 2. Currently working at KCMH 3. Have been working at KCMH for more than 3 months 4. Involved in providing care to patients attending the Headache Clinic 5. Able to communicate in Thai fluently 6. Provide informed consent * Exclusion Criteria Group 1: People with migraine with or without aura or chronic migraine 1. Participants who cannot completely participate in an in-depth interview (IDI) and questionnaires, either in-person or online 2. Participants with headache disorders other than migraine with or without aura or chronic migraine 3. Alcohol or drug use that, in the opinion of the investigator, would interfere with completion of study procedures 4. A known history of allergy to eptinezumab Group 2: Healthcare providers <!-- --> 1. Participants who cannot completely participate in an IDI, either in-person or online